Collateral for a security interest recorded Oct 19, 2022 (Orbimed Royalty & Credit Opportunities IV, LP).
Term ends Jan 21, 2035 · Low confidence
20-year base term ends Jan 21, 2035
Held by AstraZeneca AB
Filed Feb 8, 2021 as application 17/170,641 · Granted Jun 6, 2023
Base term plus 232 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2015
2035
Clock starts
Jan 21, 2015
Jan 21, 2015
Term ends
Jan 21, 2035
Jan 21, 2035
Granted
Jun 6, 2023
Jun 6, 2023
base term
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
232
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 10,287,258, US 10,669,245, US 11,117,874, US 11,655,221, US 11,655,222, US 11,655,223, US 11,655,224, US 11,673,871, US 11,673,872, US 11,680,049, US 11,773,069, US 11,814,359, US 9,522,894, US 9,815,805.
0 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
19
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 232 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 0 of 2 maintenance fees are paid so far. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 21, 2015, when application 14/601,371, the earliest non-provisional in its chain, was filed (this one was filed Feb 8, 2021); a parent in its chain could not be resolved (the next row) | Jan 21, 2035 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +232 days, USPTO patent term adjustment record | Sep 10, 2035 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,287,258, US 10,669,245, US 11,117,874, US 11,655,221, US 11,655,222, US 11,655,223, US 11,655,224, US 11,673,871, US 11,673,872, US 11,680,049, US 11,773,069, US 11,814,359, US 9,522,894, US 9,815,805) | capped to Jan 21, 2035 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 2 maintenance fees paid | In force | High confidence |
| Further caveats on record | The record names parents not resolved: 16855522, 16358091, 14601371, 14601371 | Low confidence overall | Low confidence |
| Computed term end | The steps above, in order | Jan 21, 2035 | Low confidence |
This family
| US 9,522,894 | In force Mar 2035 | Mar 2035 |
| US 9,815,805 | In force Jan 2035 | Jan 2035 |
| US 10,287,258 | In force Jan 2035 | Jan 2035 |
| US 10,669,245 | In force Jan 2035 | Jan 2035 |
| US 11,117,874 | In force Jan 2035 | Jan 2035 |
| US 11,667,615 | this patent Jan 2035 | Jan 2035 |
| US 11,773,069 | In force Jan 2035 | Jan 2035 |
| US 11,655,221 | In force Jan 2035 | Jan 2035 |
8 of 19 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Feb 23, 2021 Reel 55378, frame 416 | Doyle, Kevin; Van de Poël, Amanda; Jones, Graham; Watson, David; Macritchie, Jaqueline; Palmer, Nicholas | Biofocus Dpi Ltd. | Assignment of Assignor's Interest |
| Feb 23, 2021 Reel 55378, frame 424 | Biofocus Dpi Ltd. | AstraZeneca AB | Assignment of Assignor's Interest |
| Feb 23, 2021 Reel 55378, frame 429 | Connolly, Stephen | AstraZeneca UK Limited | Assignment of Assignor's Interest |
| Feb 23, 2021 Reel 55378, frame 442 | Lönn, Hans Roland; Pontén, John Fritiof; Aurell, Carl-johan; Karlsson, Staffan Po | AstraZeneca AB | Assignment of Assignor's Interest |
| Feb 24, 2021 Reel 55386, frame 550 | AstraZeneca UK Limited | AstraZeneca AB | Assignment of Assignor's Interest |
| Oct 19, 2022 Reel 61727, frame 39 | Insmed Incorporated | Orbimed Royalty & Credit Opportunities IV, LP | Second Lien Patent Security Agreement |
| Oct 20, 2022 Reel 61735, frame 875 | Insmed Incorporated | Biopharma Credit PLC | Patent Security Agreement |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jan 2035
Term ends Jan 21, 2035. Maintenance fees still fall due before then
Note
The 232 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 10,287,258, US 10,669,245, US 11,117,874, US 11,655,221, US 11,655,222, US 11,655,223, US 11,655,224, US 11,673,871, US 11,673,872, US 11,680,049, US 11,773,069, US 11,814,359, US 9,522,894, US 9,815,805.
Citations
19
later US patents cite this one
That is top 5% of utility patents granted in 2023 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.